ArticleEBioMedicine2026
Antibody-mediated targeting of SOSIP HIV-1 Env to skin Langerhans cells potentiates humoral responses.
Article in EBioMedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDespite decades of research and multiple phase 2b/3 trials, an effective HIV vaccine remains out of reach. A key obstacle is the need for innovative delivery strategies that can induce potent and durable protective immune responses. Targeting antigen-presenting cells in the skin, specifically Langerhans cells (LCs), offers a promising approach to enhance vaccine efficacy by promoting early and efficient activation of the humoral immune system.
methodsWe developed an Antibody-Mediated targeting Vaccine (AMV) platform that delivers HIV-1 Env trimeric antigens directly to LCs via an anti-Langerin scFv domain. Two constructs were tested: LC
findingsWe show that, as compared to an anti-Langerin mAb fused with Env monochains, LC-targeted delivery of Env
interpretationThese results validate LC-targeting as an efficient, adjuvant-free, strategy for inducing potent humoral responses against HIV-1. The AMV platform enables precise delivery of structurally intact Env trimers to skin-resident LCs facilitating early B cell activation and maturation. This approach offers distinct advantages over conventional adjuvanted sub-unit protein vaccines supporting its potential for clinical translation.
fundingThis work was supported by Inserm, the Vaccine Research Institute (VRI), the French National Research Agency (ANR-10-LABX-77, ANR-10-INBS-05-02, ANR-10-EURE-0003), and the European Union's Horizon 2020 (grant 681032).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.